. | ‘މ–b | –O˜aމ–b | ƒgƒ‰ƒ“ƒXމ–b | ƒRƒŒƒXƒeƒ[ƒ‹ |
¢ŠE•ÛŒ’‹@\WHO‚Ì–Ú•W—Ê | 15-30% | 10%–¢–ž | 1%–¢–ž | 300mg/“ú–¢–ž |
•Ä‘S‘Ÿ‹¦‰ïAHA‘ål‚Ì–Ú•W—Ê | . | 7%–¢–ž | 1%–¢–ž | 300mg/“ú–¢–ž |
•Ä‘S‘Ÿ‹¦‰ïAHA4-18΂̖ڕW—Ê | 25-35% | ‚È‚ | ‚È‚ | . |
•Ä‘ŠwZ‹‹H‚ÌŠî€ | 30%ˆÈ‰º | 10%–¢–ž | . | ‚È‚ |
‰p‘ŠwZ‹‹H‚ÌŠî€ | 35%ˆÈ‰º | 11%ˆÈ‰º | 2%ˆÈ‰º | . |
“ú–{l‚ÌHŽ–ÛŽæŠî€ | . | . | . | . |
30-69Î@’j« | 20-25% | 4.5-7.0% | . | 750mg/“ú–¢–ž |
30-69Î@—« | 20-25% | 4.5-7.0% | . | 600mg/“ú–¢–ž |
18-29Î@’j« | 20-30% | 4.5-7.0% | . | 750mg/“ú–¢–ž |
18-29Î@—« | 20-30 | 4.5-7.0% | . | 600mg/“ú–¢–ž |
6-17Î ’j« | 20-30% | . | . | . |
6-17Î —« | 20-30% | . | . | . |
“Œ‹ž“sŠwZ‹‹H‚ÌŠî€ | 25-30% | . | . | . |